<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: To potentially reduce late effects of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD), <z:e sem="disease" ids="C0014130" disease_type="Disease or Syndrome" abbrv="">endocrinopathy</z:e>, and <z:hpo ids='HP_0000789'>infertility</z:hpo> in patients with Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo> (FA) undergoing HLA-matched related donor hematopoietic cell transplantation (HCT), we developed a regimen using fludarabine (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FLU</z:e>), <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY), and anti-thymocyte globulin (ATG) followed by infusion of T-cell depleted (TCD) bone marrow (BM) or unmanipulated umbilical cord blood (UCB) </plain></SENT>
<SENT sid="1" pm="."><plain>GVHD prophylaxis consisted of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and short course <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>PROCEDURE: Between April 2000 and June 2003, 11 patients (10 <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA), 1 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)) underwent HCT using this regimen </plain></SENT>
<SENT sid="3" pm="."><plain>Stem cell sources were BM and UCB in eight and three patients, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> patients demonstrated primary engraftment </plain></SENT>
<SENT sid="5" pm="."><plain>Median days to neutrophil and platelet engraftment were 11 days (range 9-21) and 38 days (range 19-381), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>No patient developed GVHD after primary HCT </plain></SENT>
<SENT sid="7" pm="."><plain>The patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> relapsed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and a maternal donor recipient experienced secondary graft failure </plain></SENT>
<SENT sid="8" pm="."><plain>For the nine FA patients with AA who underwent HLA-identical sibling donor HCT, the Kaplan-Meier estimates of overall survival and event-free survival (EFS) at 2 years are 100% and 82%, respectively, at a median follow-up of 2.9 years (range 1.9-4.8) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In summary, a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FLU</z:e>-based, non-irradiation approach is effective for FA patients with AA undergoing HLA-identical sibling donor HCT </plain></SENT>
</text></document>